Adil Daud
University of California, San Francisco
H-index: 84
North America-United States
Top articles of Adil Daud
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors | World Journal of Surgical Oncology | Paul Wong Andrew D Wisneski Katy K Tsai Tammy T Chang Kenzo Hirose | 2024/3/11 |
Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma | Alexandra Haugh Adil I Daud | 2024/2/8 | |
Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations | bioRxiv | Harish Vasudevan Alexandra M Haugh Robert C Osorio Rony A Francois Michael E Tawil | 2024 |
Intratumoral (ITu) delivery of mRNA-2752 encoding human OX40L/IL-23/IL-36γ in combination with durvalumab induces an immunostimulatory effect within the tumor microenvironment … | Cancer Research | Michael Abadier Ryan J Sullivan Jacky Chow Vasudha Sehgal Randy F Sweis | 2024/3/22 |
1274 Infliximab for decompensated diabetes following immune checkpoint inhibitor therapy | Robert J Weber Christine Kim Adil Daud Mark Anderson Zoe Quandt | 2023/11/1 | |
First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors. | Adil Daud Costantine Albany Vamsidhar Velcheti Ralph J Hauke Jordi Rodon Ahnert | 2023/6/1 | |
The therapeutically actionable long non-coding RNA ‘T-RECS’is essential to cell survival in NRAS/MAPK-driven melanoma | Valentin Feichtenschlager Linan Chen Yixuan James Zheng Wilson Ho Martina Sanlorenzo | 2023/9/27 | |
Initial evidence for the efficacy of naporafenib in combination with trametinib in NRAS-mutant melanoma: Results from the expansion arm of a phase Ib, open-label study | Journal of Clinical Oncology | Filippo de Braud Christophe Dooms Rebecca S Heist Celeste Lebbe Martin Wermke | 2023/5/10 |
Seven-year follow-up of the phase III KEYNOTE-006 study: pembrolizumab versus ipilimumab in advanced melanoma | Journal of Clinical Oncology | Caroline Robert Matteo S Carlino Catriona McNeil Antoni Ribas Jean-Jacques Grob | 2023/8/20 |
Pembrolizumab-associated chronic rhinosinusitis: A new endotype and management considerations | International Forum of Allergy & Rhinology | Taylor C Standiford Neil N Patel Amritpal Singh Grant Gochman Tara Jamie Wu | 2023/12 |
Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy | Clinical Radiology | Y Li RR Flavell R Juarez M Chow C Wu | 2023/2/1 |
Resistance to Immune Checkpoint Blockade: IFNγ or MHC-I? | Cancer Immunology Research | Alexandra Haugh Adil Daud | 2023/7/5 |
714 Phase 1a trial of PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, as monotherapy and in combination with pembrolizumab, in treatment-resistant patients with advanced or … | Adil Daud Chris N Barnes Susan Owen Scott M Turner Mario Sznol | 2023/11/1 | |
Pulsed electric fields in oncology: A snapshot of current clinical practices and research directions from the 4th world congress of electroporation | Luca G Campana Adil Daud Francesco Lancellotti Julio P Arroyo Rafael V Davalos | 2023/6/25 | |
Method for the treatment of malignancies | 2020/10/6 | ||
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma | Cancer chemotherapy and pharmacology | Drew W Rasco Theresa Medina Pippa Corrie Anna C Pavlick Mark R Middleton | 2023/7 |
775 Phase Ib/II Study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint Inhibitor therapy with … | Saya Jacob Markee Micu Zoe Quandt Katy K Tsai Shahriar Yaghoubi | 2023/11/1 | |
Phase Ib/II study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint inhibitor therapy with and … | Saya Jacob Adil Daud | 2023/6/1 | |
Phase 1 study of SGN-BB228, an investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific, in patients with advanced melanoma and other solid tumors (SGNBB228-001). | Jason Timothy Henry Janice M Mehnert Erika Rudnicki Juan Pinelli Adil Daud | 2023/6/1 | |
TCR-sequencing in cancer and autoimmunity: barcodes and beyond | Kristen E Pauken Kaitlyn A Lagattuta Benjamin Y Lu Liliana E Lucca Adil I Daud | 2022/1/25 |
Co-Authors
